Innovent Biologics reports significant clinical success with picankibart in psoriasis treatment
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: IBI112), signaling a major breakthrough in psoriasis treatment. The study demonstrated that picankibart, a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, met all primary and key secondary endpoints, showcasing its […]